• 1  Fransen M, Karahalios A, Sharma N, English DR, Giles GG, Sinclair RD. Non‐melanoma skin cancer in Australia. Med J Aust 2012;197(10):565–8. Cross Ref link Pubmed link
  • 2  Staples MP, Elwood M, Burton RC, Williams JL, Marks R, Giles GG. Non‐melanoma skin cancer in Australia: the 2002 national survey and trends since 1985. Med J Aust 2006;184(1):6–10. Pubmed link
  • 3  Hussain SK, Sundquist J, Hemminki K. Incidence trends of squamous cell and rare skin cancers in the Swedish national cancer registry point to calendar year and age‐dependent increases. J Invest Dermatol 2010;130(5):1323–8. Cross Ref link Pubmed link
  • 4  Iversen T, Tretli S. Trends for invasive squamous cell neoplasia of the skin in Norway. Br J Cancer 1999;81(3):528–31. Cross Ref link Pubmed link
  • 5  Doherty VR, Brewster DH, Jensen S, Gorman D. Trends in skin cancer incidence by socioeconomic position in Scotland, 1978‐2004. Br J Cancer 2010;102(11):1661–4. Cross Ref link Pubmed link
  • 6  Bath‐Hextall F, Leonardi‐Bee J, Smith C, Meal A, Hubbard R. Trends in incidence of skin basal cell carcinoma. Additional evidence from a UK primary care database study. Int J Cancer 2007;121(9):2105–8.
  • 7  Birch‐Johansen F, Jensen A, Mortensen L, Olesen AB, Kjær SK. Trends in the incidence of nonmelanoma skin cancer in Denmark 1978‐2007: rapid incidence increase among young Danish women. Int J Cancer 2010;127(9):2190–8. Cross Ref link Pubmed link
  • 8  Plesko I, Severi G, Obsitníková A, Boyle P. Trends in the incidence of non‐melanoma skin cancer in Slovakia, 1978–1995. Neoplasma 2000;47(3):137–42. Pubmed link
  • 9  Diepgen TL, Drexler H, Schmitt J. Epidemiology of occupational skin cancer due to UV‐irradiation. Hautarzt 2012;63(10):769–77. Cross Ref link Pubmed link
  • 10  Simpson CR, Newton J, Hippisley‐Cox J, Sheikh A. Trends in the epidemiology and prescribing of medication for eczema in England. J R Soc Med 2009;102(3):108–17. Cross Ref link Pubmed link
  • 11  Stensen L, Thomsen SF, Backer V. Change in prevalence of atopic dermatitis between 1986 and 2001 among children. Allergy Asthma Proc 2008;29(4):392–6. Cross Ref link Pubmed link
  • 12  Olesen AB, Bang K, Juul S, Thestrup‐Pedersen K. Stable incidence of atopic dermatitis among children in Denmark during the 1990s. Acta Derm Venereol 2005;85(3):244–7. Pubmed link
  • 13  Grize L, Gassner M, Wüthrich B, et al. Trends in prevalence of asthma, allergic rhinitis and atopic dermatitis in 5–7‐year old Swiss children from 1992 to 2001. Allergy 2006;61(5):556–62. Cross Ref link Pubmed link
  • 14  Margolis DJ, Bilker W, Santanna J, Baumgarten M. Venous leg ulcer: incidence and prevalence in the elderly. J Am Acad Dermatol 2002;46(3):381–6. Cross Ref link Pubmed link
  • 15  Ruckley CV. Socioeconomic impact of chronic venous insufficiency and leg ulcers. Angiology 1997;48(1):67–9. Cross Ref link Pubmed link
  • 16  Robinson R. Economic evaluation in health care – what does it mean? BMJ 1993;(307):670–3. Cross Ref link Pubmed link
  • 17  Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Basic Types of Economic Evaluation of Health Care Programmes, 3rd edn. Oxford: Oxford University Press, 2005.
  • 18  Icks A, Chernyak N, Bestehorn K, et al. Methods of health economic evaluation for health services research. Gesundheitswesen 2010;72(12):917–33. Cross Ref link Pubmed link
  • 19  Tandvards och Lakemedelsformansverket (TLV). Handbook – reviewing the reimbursment status of pharmaceuticals, 2012 http://www.tlv.se (last accessed August 2014).
  • 20  National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal 2013, 2013 http://publications.nice.org.uk/pmg9 (last accessed July 2014).
  • 21  Institute for Quality and Efficiency in Health Care (IQWiG). General Methods for the Assessment of the Relation of Benefits to Costs, 2009. https://www.iqwig.de/download/General_Methods_for_the_Assessment_of_the_Relation_of_Benefits_to_Costs.pdf (last accessed October 2014).
  • 22  López‐Bastida J, Oliva J, Antoñanzas F, et al. Spanish recommendations on economic evaluation of health technologies. Eur J Health Econ 2010;11(5):513–20. Cross Ref link Pubmed link
  • 23  Collège des Économistes de la Santé. French guidelines for the economic evaluation of health care technologies, 2004. http://www.ispor.org/peguidelines/source/France_Guidelines_HE_Evaluation.pdf (last accessed October 2014).
  • 24  Krol M, Brouwer W, Rutten F. Productivity costs in economic evaluations: past, present, future. Pharmacoeconomics 2013;31(7):537–49. Cross Ref link Pubmed link
  • 25  Evans C, Mertzanis P, Abetz L. Measurement strategies for indirect costs in economic evaluations. Expert Rev Pharmacoecon Outcomes Res 2003; 3(6):703–16. Cross Ref link Pubmed link
  • 26  Prinsen CA, Korte J de, Augustin M, et al. Measurement of health‐related quality of life in dermatological research and practice: outcome of the EADV Taskforce on Quality of Life. J Eur Acad Dermatol Venereol 2013;27(10):1195–203. Pubmed link
  • 27  Augustin M, Langenbruch A, Gutknecht M, Radtke MA, Blome C. Quality of life measures for dermatology: definition, evaluation, and interpretation. Curr Derm Rep 2012;1(3):148–59. Cross Ref link
  • 28  Both H, Essink‐Bot M, Busschbach J, Nijsten T. Critical review of generic and dermatology‐specific health‐related quality of life instruments. J Invest Dermatol 2007;127(12):2726–39. Cross Ref link Pubmed link
  • 29  Ware JE, Gandek B. Overview of the SF‐36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol 1998;51(11):903–12. Cross Ref link Pubmed link
  • 30  EuroQol. EuroQol – a new facility for the measurement of health‐related quality of life. Health Policy 1990;16(3):199–208. Cross Ref link Pubmed link
  • 31  Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19(3):210–16. Cross Ref link Pubmed link
  • 32  Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ. Skindex, a quality‐of‐life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol 1996;107(5):707–13. Cross Ref link Pubmed link
  • 33  Finlay AY, Kelly SE. Psoriasis – an index of disability. Clin Exp Dermatol 1987;12(1):8–11. Cross Ref link Pubmed link
  • 34  Torrence GW. Measurement of health state utilities for economic appraisal: a review. J Health Econ 1986;(5):1–30. Cross Ref link Pubmed link
  • 35  Hall JMG. What every doctor should know about economics: the benefits of economic appraisal. Med J Australia 1992; (152):80–2. Pubmed link
  • 36  Bickers DR, Lim HW, Margolis D, et al. The burden of skin diseases: 2004, a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol 2006;55(3):490–500. Cross Ref link Pubmed link
  • 37  Katalinic A, Kunze U, Schäfer T. Epidemiology of cutaneous melanoma and non‐melanoma skin cancer in Schleswig‐Holstein, Germany: incidence, clinical subtypes, tumour stages and localization (epidemiology of skin cancer). Br J Dermatol 2003;149(6):1200–6. Cross Ref link Pubmed link
  • 38  Chren M, Torres JS, Stuart SE, Bertenthal D, Labrador RJ, Boscardin WJ. Recurrence after treatment of nonmelanoma skin cancer: a prospective cohort study. Arch Dermatol 2011;147(5):540–6. Cross Ref link Pubmed link
  • 39  Seidler AM, Pennie ML, Veledar E, Culler SD, Chen SC. Economic burden of melanoma in the elderly population: population‐based analysis of the Surveillance, Epidemiology, and End Results (SEER) – Medicare data. Arch Dermatol 2010;146(3):249–56. Cross Ref link Pubmed link
  • 40  Ekwueme DU, Guy GP, Li C, Rim SH, Parelkar P, Chen SC. The health burden and economic costs of cutaneous melanoma mortality by race/ethnicity – United States, 2000 to 2006. J Am Acad Dermatol 2011;65(5 Suppl. 1):S133–43. Cross Ref link Pubmed link
  • 41  Morris S, Cox B, Bosanquet N. Cost of skin cancer in England. Eur J Health Econ 2009;10:267–73. Cross Ref link Pubmed link
  • 42  Tinghög G, Carlsson P, Synnerstad I, Rosdahl I. Societal cost of skin cancer in Sweden in 2005. Acta Derm Venereol 2008;88(5):467–73. Cross Ref link Pubmed link
  • 43  Chevalier J, Bonastre J, Avril M. The economic burden of melanoma in France: assessing healthcare use in a hospital setting. Melanoma Res 2008;18(1):40–6. Cross Ref link Pubmed link
  • 44  Stang A, Stausberg J, Boedeker W, Kerek‐Bodden H, Jöckel K. Nationwide hospitalization costs of skin melanoma and non‐melanoma skin cancer in Germany. J Eur Acad Dermatol Venereol 2008;22(1):65–72. Pubmed link
  • 45  Breitbart EW, Waldmann A, Nolte S, et al. Systematic skin cancer screening in Northern Germany. J Am Acad Dermatol 2012;66(2):201–11. Cross Ref link Pubmed link
  • 46  Federman DG, Kirsner RS, Viola KV. Skin cancer screening and primary prevention: facts and controversies. Clin Dermatol 2013;31(6):666–70. Cross Ref link Pubmed link
  • 47  Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom: a population‐based study. Arch Dermatol 2005;141(12):1537–41. Cross Ref link Pubmed link
  • 48  Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M. Co‐morbidity and age‐related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol 2010;90(2):147–51. Cross Ref link Pubmed link
  • 49  Ferrándiz C, Bordas X, García‐Patos V, Puig S, Pujol R, Smandía A. Prevalence of psoriasis in Spain (Epiderma Project: phase I). J Eur Acad Dermatol Venereol 2001;15(1):20–3. Cross Ref link Pubmed link
  • 50  Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin Dermatol 2007;25(6):535–46. Cross Ref link Pubmed link
  • 51  Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Schäfer I. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 2010;162(3):633–6. Cross Ref link Pubmed link
  • 52  Armstrong AW, Schupp C, Wu J, Bebo B. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003–2011. PLOS One 2012;7(12):e52935. Cross Ref link Pubmed link
  • 53  Levy AR, Davie AM, Brazier NC, et al. Economic burden of moderate to severe plaque psoriasis in Canada. Int J Dermatol 2012;51(12):1432–40. Cross Ref link Pubmed link
  • 54  Navarini AA, Laffitte E, Conrad C, et al. Estimation of cost‐of‐illness in patients with psoriasis in Switzerland. Swiss Med Wkly 2010;140(5–6):85–91. Pubmed link
  • 55  Sohn S, Schoeffski O, Prinz J, et al. Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost‐of‐illness study. Dermatology (Basel) 2006;212(2):137–44. Cross Ref link Pubmed link
  • 56  Berger K, Ehlken B, Kugland B, Augustin M. Cost‐of‐illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. J Dtsch Dermatol Ges 2005;3(7):511–18. Cross Ref link Pubmed link
  • 57  Yu AP, Tang J, Xie J, et al. Economic burden of psoriasis compared to the general population and stratified by disease severity. Curr Med Res Opin 2009;25(10):2429–38. Cross Ref link Pubmed link
  • 58  Carrascosa JM, Pujol R, Daudén E, et al. A prospective evaluation of the cost of psoriasis in Spain (EPIDERMA project: phase II). J Eur Acad Dermatol Venereol 2006;20(7):840–5. Pubmed link
  • 59  Colombo G, Altomare G, Peris K, et al. Moderate and severe plaque psoriasis: cost‐of‐illness study in Italy. Ther Clin Risk Manag 2008;4(2):559–68. Pubmed link
  • 60  Akobundu E, Ju J, Blatt L, Mullins CD. Cost‐of‐illness studies: a review of current methods. Pharmacoeconomics 2006;24(9):869–90. Cross Ref link Pubmed link